Profile | GDS2987 / GI_6679187-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 6.9 | 25 |
GSM215244 | HMVEC_vehicle_rep2 | 9.3 | 24 |
GSM215253 | HMVEC_vehicle_rep3 | 11.9 | 38 |
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 2.9 | 7 |
GSM215344 | HMVEC_atorvastatin_rep2 | 25 | 51 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 31.7 | 52 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 15.2 | 30 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 69.4 | 69 |
GSM215294 | HMVEC_SLx2119_rep1 | 10.3 | 36 |
GSM215295 | HMVEC_SLx2119_rep2 | 16.7 | 33 |
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 41 | 52 |
GSM215298 | PASMC_vehicle_rep2 | 50.1 | 60 |
GSM215310 | PASMC_vehicle_rep3 | 31.4 | 45 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 27.7 | 41 |
GSM215313 | PASMC_atorvastatin_rep3 | 62.9 | 65 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 53.5 | 63 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 1.1 | 2 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 49.5 | 61 |
GSM215327 | PASMC_SLx2119_rep1 | 29 | 45 |
GSM215328 | PASMC_SLx2119_rep2 | 3.9 | 7 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 8.1 | 23 |
GSM215332 | Fibroblasts_vehicle_rep3 | 11.5 | 36 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 29.1 | 56 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 19.5 | 52 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 5.5 | 18 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 13.5 | 36 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 11.9 | 34 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 32.8 | 62 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 22.4 | 48 |